New research will focus on improving target therapies, such as new BRAF/MEK inhibitors, using FGFR inhibitors, Raf inhibitors, or a combination of multiple therapies, in relapsing rare glial and/or neuronal tumours after surgery or surgically inaccessible tumours. Here, BRAF is linked to neoplasm.